Humacyte (NASDAQ:HUMA) Stock Rating Upgraded by EF Hutton Acquisition Co. I

Humacyte (NASDAQ:HUMA) was upgraded by analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports.

Other analysts have also recently issued reports about the stock. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price target on shares of Humacyte in a research note on Tuesday, July 2nd. BTIG Research boosted their price objective on shares of Humacyte from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 15th. Finally, Benchmark reiterated a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research note on Thursday, September 5th. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $8.60.

Humacyte Trading Down 2.6 %

NASDAQ HUMA opened at $5.25 on Monday. The business’s fifty day moving average is $6.93 and its 200-day moving average is $5.53. The company has a debt-to-equity ratio of 0.61, a current ratio of 5.41 and a quick ratio of 5.41. The stock has a market capitalization of $626.59 million, a price-to-earnings ratio of -5.25 and a beta of 1.47. Humacyte has a one year low of $1.96 and a one year high of $9.97.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). Equities research analysts predict that Humacyte will post -1.09 EPS for the current year.

Insider Buying and Selling at Humacyte

In other news, Director Brady W. Dougan sold 252,676 shares of the company’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total value of $1,695,455.96. Following the completion of the transaction, the director now directly owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Humacyte news, CFO Dale A. Sander sold 39,389 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $6.68, for a total value of $263,118.52. Following the completion of the sale, the chief financial officer now owns 2,000 shares in the company, valued at $13,360. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brady W. Dougan sold 252,676 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $6.71, for a total transaction of $1,695,455.96. Following the completion of the transaction, the director now owns 4,306,464 shares in the company, valued at approximately $28,896,373.44. The disclosure for this sale can be found here. Insiders sold a total of 921,267 shares of company stock worth $5,987,258 over the last three months. 23.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Humacyte

Several institutional investors have recently added to or reduced their stakes in the company. nVerses Capital LLC purchased a new stake in shares of Humacyte during the second quarter worth about $28,000. Victory Capital Management Inc. purchased a new stake in Humacyte in the 4th quarter worth approximately $29,000. China Universal Asset Management Co. Ltd. grew its position in shares of Humacyte by 65.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company’s stock worth $62,000 after buying an additional 7,897 shares during the last quarter. Hartline Investment Corp purchased a new position in shares of Humacyte during the first quarter valued at approximately $70,000. Finally, Principal Financial Group Inc. bought a new position in shares of Humacyte during the second quarter valued at approximately $83,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.